CGRP monoclonal antibodies (mAbs)
- Migraine-prevention biologics
- Monthly/quarterly injection; rapid onset possible
- Erenumab blocks receptor; others bind ligand
- Minimal CYP drug interactions
- Constipation/hypertension notable with erenumab
- Injection-site reactions are common
- Now accepted as first-line preventive options
Class at a glance
- Migraine-prevention biologics
Pharmacology
- Erenumab blocks receptor; others bind ligand
- Minimal CYP drug interactions
Dosing / safety
- Monthly/quarterly injection; rapid onset possible
- Constipation/hypertension notable with erenumab
Safety / clinical role
- Injection-site reactions are common
- Now accepted as first-line preventive options
Self-check
- Which CGRP antibody blocks the receptor rather than the ligand?
Erenumab. - Which adverse effects are notable with erenumab?
Constipation and hypertension.
Drugs in this class (4)
CGRP monoclonal antibodies (mAbs) prescription history
Animated chart of estimated U.S. prescriptions per year, Migraine-specific meds (1936–2026). CGRP antibodies highlighted from 2018.
All drug classes · Open CGRP monoclonal antibodies (mAbs) in the interactive console ↗